10-Q: Alnylam Pharmaceuticals Reports Strong Q1 2026 Results

Alnylam Pharmaceuticals announced a significant increase in total revenues, driven by strong product sales, particularly AMVUTTRA, and improved operational income.

Summary

• Alnylam Pharmaceuticals reported total revenues of $1.167 billion for the first quarter of 2026, a 96% increase compared to $594.2 million in the same period of 2025.
• Net product revenues surged by 121% to $1.036 billion, primarily due to substantial growth in AMVUTTRA sales, which increased by 187% to $889.9 million.
• Income from operations reached $268.6 million, a significant improvement from $18.1 million in Q1 2025.
• The company reported a net income of $206.0 million for the quarter, a substantial turnaround from a net loss of $18.3 million in the prior year period.
• Research and development expenses increased by 38% to $364.9 million, while selling, general, and administrative expenses rose by 34% to $322.6 million, reflecting investments in pipeline advancement and commercialization efforts.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the significant revenue growth, achievement of profitability, and strong product performance, indicating a healthy and expanding business.

Positives

• Total revenues increased by 96% to $1.167 billion in Q1 2026.
• Net product revenues grew by 121% to $1.036 billion, driven by strong performance of AMVUTTRA and other products.
• AMVUTTRA sales saw a remarkable 187% increase, reaching $889.9 million.
• Income from operations improved significantly, reaching $268.6 million, up from $18.1 million in the prior year.
• The company achieved profitability with a net income of $206.0 million, compared to a net loss of $18.3 million in Q1 2025.
• Royalty revenue increased by 85% to $49.0 million, primarily from Leqvio sales.
• Cash, cash equivalents, and marketable securities stood at $3.01 billion as of March 31, 2026, indicating a strong liquidity position.

Negatives

• Cost of goods sold increased by 196% to $207.5 million, and as a percentage of net product revenues, it rose from 15.0% to 20.0%, largely due to increased AMVUTTRA sales and associated royalty rates.
• Net revenues from collaborations decreased by 17% to $82.1 million, mainly due to a one-time payment recognized in the prior year's quarter from an amendment with Vir Biotechnology.
• Net product revenues for ONPATTRO decreased by 59% to $20.5 million.
• Total other expense, net, increased by 130% to $47.0 million, driven by higher interest expense and foreign currency losses.

Risks

• The commercial success of AMVUTTRA and the ability to sustain and grow its revenue depend on various factors, including safety and efficacy, reimbursement policies, competitive therapies, and manufacturing and supply.
• The company may not be able to sustain profitability or positive cash flow from operations.
• Future capital requirements may necessitate seeking additional funding, potentially through equity offerings or debt financing, which could dilute existing stockholders or impose onerous terms.
• The company relies on third-party collaborators for development and commercialization of certain products, and any failure or termination of these collaborations could adversely affect business prospects.
• The company relies on third-party manufacturers (CMOs) for product supply, and any disruption or failure by these CMOs could impact clinical trials and commercial supply.
• The company faces intense competition from existing drugs, new treatment methods, and emerging technologies in the pharmaceutical market.
• The company is subject to extensive governmental regulations and legal obligations related to healthcare, privacy, data protection, and marketing practices, with potential for significant penalties for non-compliance.
• The company's stock price has been and may continue to be volatile.
• The company has significant convertible debt outstanding, and its ability to service this debt or make cash payments upon conversion could be impacted by future performance.
• The company is subject to intellectual property litigation and challenges, which can be costly and divert management resources.

Future Outlook

The company expects to continue investing significantly in research and development to advance its RNAi platform and clinical pipeline, aiming to achieve its Alnylam 2030 strategy goals, which include expanding to 10 tissue types, advancing over 40 clinical programs, delivering at least two new transformative medicines beyond TTR with blockbuster potential, investing approximately 30% of revenues in R&D, and achieving a 25%+ total revenue compound annual growth rate with approximately 30% non-GAAP operating margin through 2030.

Management Comments

• We achieved profitability for the first time in 2025. Nevertheless, we have incurred significant losses since inception, and as of March 31, 2026, we had an accumulated deficit of $6.50 billion.
• With the achievement of profitability in 2025, going forward we expect to be able to fund our operations primarily from product revenues, which we expect will be supplemented by collaboration revenue and royalty revenue from products commercialized by our collaborators.
• We expect to continue investing significantly in research and development to advance our RNAi platform and clinical pipeline.
• Assuming successful development and regulatory approval, we believe that with its anticipated product profile, nucresiran has the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and operating income margin.
• We expect our cost of goods sold, including cost of goods sold as a percentage of net product revenues, will increase during 2026, as compared to 2025, primarily as a result of an expected increase in sales of AMVUTTRA and an associated increase in the royalty rate payable on net sales of AMVUTTRA.

Industry Context

StockSavvy.ai notes that Alnylam's strong performance in Q1 2026, particularly the significant growth in AMVUTTRA sales and the achievement of profitability, aligns with the broader trend of increasing adoption and commercial success of RNAi therapeutics. The company's continued investment in R&D and expansion of its pipeline demonstrate a commitment to leveraging its platform for future growth in a competitive biopharmaceutical landscape.

Legal Proceedings

• The Board of Regents of the University of Texas System filed a lawsuit alleging infringement of U.S. Patent No. 8,895,717 by ONPATTRO, which has been transferred to the U.S. District Court for the District of Massachusetts.
• Alnylam and its collaborators filed a patent infringement lawsuit against Cipla USA Inc. and Cipla Ltd. based on Cipla's ANDA seeking approval for a generic version of Leqvio.
• Received a subpoena from the U.S. Attorneys Office for the District of Massachusetts seeking documents pertaining to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI.

Stakeholder Impact

• Shareholders are likely to see positive impact from the strong financial performance and improved profitability.
• Employees may benefit from the company's growth and continued investment in R&D and commercialization, potentially leading to job creation and career advancement opportunities.
• Patients will benefit from the continued availability and potential expansion of indications for Alnylam's RNAi therapeutics, such as AMVUTTRA.
• Collaborators and partners, such as Roche, Regeneron, Sanofi, and Novartis, will continue to benefit from the strategic alliances and potential milestone and royalty payments.

Next Steps

• Continue global commercial launch of AMVUTTRA for ATTR-CM.
• Advance late-stage programs, including Phase 3 trials for nucresiran (TRITON-PN and TRITON-CM) and zilebesiran (ZENITH).
• Progress early-stage clinical pipeline, including CNS and metabolic programs.
• Continue efforts to deliver RNAi therapeutics to additional tissues and treat new disease areas.
• Selectively pursue complementary modalities through business development.
• Prepare for future commercial product launches.
• Continue to expand global development, regulatory, manufacturing, quality, compliance, and marketing and sales capabilities.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance with significant revenue growth and a strong turnaround to profitability. The robust sales of AMVUTTRA, coupled with a promising pipeline and strategic collaborations, indicate strong future growth potential. The company's solid liquidity position further supports a positive outlook, making it an attractive investment.

Keywords

Alnylam Pharmaceuticals, Form 10-Q, Quarterly Report, RNAi therapeutics, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, financial results, revenue, net income, R&D expenses, SG&A expenses, biopharmaceutical